Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

PHASE4CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

March 19, 2016

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Multiple Sclerosis (MS)
Interventions
DRUG

Tecfidera

Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.

DRUG

Placebo

Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.

Trial Locations (11)

10032

MS Clinical Care and Research Center, Dept of Neurology, Columbia University, New York

21287

Johns Hopkins University - Neurology, Baltimore

55905

Mayo Clinic Department of Neurology, Rochester

63110

Washington University Department of Neurology, St Louis

73104

Oklahoma Medical Research Foundation, MS Center of Excellence, Oklahoma City

75246

MS Treatment Center of Dallas, Dallas

89106

Cleveland Clinic - Lou Ruvo Center for Brain Health, Las Vegas

90089

Keck School of Medicine - USC - Department of Neurology, Los Angeles

98122

Swedish Medical Center, Seattle

98405

MultiCare Institute for Research and Innovation, Tacoma

75390-8806

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Biogen

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER

NCT02739542 - Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) | Biotech Hunter | Biotech Hunter